Table 1. Patient characteristics

VariableStable Transplant (n = 22)Acute Clinical Rejection (n = 18)ATN (n = 5)Recurrent or de novo Glomerulopathy (n = 5)
a P = 0.003 versus stable transplant group.
b P < 0.001 versus stable transplant group.
c P = 0.14 versus acute clinical rejection group. P < 0.001 versus recurrent or de novo glomerulopathy group.
d Not included for statistical analysis.
e Not included for statistical comparison (3 of 5 patients were on hemodialysis).
Female gender, n (%)12 (55)6 (33)22
Age, mean ± SD45 ± 1343 ± 1040 ± 1847 ± 9
Caucasian race, n (%)14 (64)15 (83)35
Nephropathy
    diabetic, n (%)6 (27)3 (17)10
    glomerulonephritis, n (%)6 (27)6 (33)34
    others, n (%)10 (46)9 (50)11
First transplant, n (%)21 (95)16 (89)54
Cadaveric donor, n (%)15 (68)10 (56)35
HLA-mismatches, median (range)3 (1–5)4 (2–5)a3 (2–4)3 (3–5)
Panel-reactive antibodies (PRA)
    peak PRA >10%, n (%)2 (9)001
    current PRA >10%, n (%)1 (5)001
Cytomegalovirus serology
    recipient neg./donor pos., n (%)3 (14)3 (17)11
    recipient neg./donor neg., n (%)7 (32)4 (22)02
    recipient pos./donor pos., n (%)4 (18)9 (50)31
    recipient pos./donor neg., n (%)8 (36)2 (11)11
Allograft biopsy
    week posttransplant, median (range)8 (3–51)8 (1–18)day 5 or 6d253 (7–442)
    rejection type (Banff 1997)
        IA (moderate tubulitis), n (%)7 (39)
        IB (severe tubulitis), n (%)8 (44)
        IIA (moderate arteritis), n (%)3 (17)
Creatinine at biopsy [μmol/L], mean ± SD91 ± 26180 ± 59b942 ± 80e122 ± 29
    % above baseline, median (range)25 (11–76)
Proteinuria at biopsy [g/L], median (range)0.07c0.093.20
(0.03–0.17)(0.03–0.28)(0.58–6.00)